CDHR2

Across TCGA pan-cancer cohorts, CDHR2 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDHR2 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher CDHR2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CDHR2 expression acts as an unfavorable survival marker, although some lineages such as STAD and UCEC show a favorable association.

SCLC, STAD, and LIHC are the cancer types where CDHR2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.110	0.627	<.001	39	view →
STAD	OS	Median	All	0.917	0.397	.017	13	view →
LIHC	DFS	Median	III,IV	0.076	0.360	.001	12	view →
ACC	OS	Median	All	0.149	0.686	.047	3	view →
UCEC	DFS	Median	All	0.899	0.621	.049	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDHR2–SCLC (DFS)

Open the SCLC breakdown →